Colleen Kusy
Stock Analyst at Baird
(3.02)
# 1,275
Out of 5,240 analysts
53
Total ratings
40.43%
Success rate
13.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Maintains: Outperform | $65 → $90 | $76.31 | +17.94% | 3 | Apr 14, 2026 | |
| CLYM Climb Bio | Maintains: Outperform | $9 → $12 | $11.41 | +5.17% | 2 | Mar 6, 2026 | |
| ARGX argenx SE | Maintains: Neutral | $858 → $867 | $802.70 | +8.01% | 2 | Feb 27, 2026 | |
| NUVL Nuvalent | Maintains: Outperform | $112 → $158 | $105.23 | +50.15% | 3 | Nov 18, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $14 → $34 | $34.29 | -0.85% | 1 | Nov 11, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $50 → $52 | $41.03 | +26.74% | 13 | Oct 31, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Outperform | $17 → $24 | $9.24 | +159.74% | 5 | Oct 3, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $40 → $52 | $43.56 | +19.38% | 3 | Jun 16, 2025 | |
| AGEN Agenus | Maintains: Neutral | $4 → $6 | $3.47 | +72.91% | 4 | Jun 4, 2025 | |
| OCS Oculis Holding AG | Maintains: Outperform | $37 → $41 | $31.37 | +30.70% | 4 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $6 | $1.71 | +251.91% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $27 → $25 | $8.60 | +190.70% | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $255 → $210 | $8.85 | +2,272.88% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $3.66 | +828.96% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $3.96 | +5,708.08% | 1 | Nov 2, 2021 |
Spyre Therapeutics
Apr 14, 2026
Maintains: Outperform
Price Target: $65 → $90
Current: $76.31
Upside: +17.94%
Climb Bio
Mar 6, 2026
Maintains: Outperform
Price Target: $9 → $12
Current: $11.41
Upside: +5.17%
argenx SE
Feb 27, 2026
Maintains: Neutral
Price Target: $858 → $867
Current: $802.70
Upside: +8.01%
Nuvalent
Nov 18, 2025
Maintains: Outperform
Price Target: $112 → $158
Current: $105.23
Upside: +50.15%
Cogent Biosciences
Nov 11, 2025
Maintains: Neutral
Price Target: $14 → $34
Current: $34.29
Upside: -0.85%
Apellis Pharmaceuticals
Oct 31, 2025
Maintains: Outperform
Price Target: $50 → $52
Current: $41.03
Upside: +26.74%
Ocular Therapeutix
Oct 3, 2025
Maintains: Outperform
Price Target: $17 → $24
Current: $9.24
Upside: +159.74%
Enliven Therapeutics
Jun 16, 2025
Maintains: Outperform
Price Target: $40 → $52
Current: $43.56
Upside: +19.38%
Agenus
Jun 4, 2025
Maintains: Neutral
Price Target: $4 → $6
Current: $3.47
Upside: +72.91%
Oculis Holding AG
Mar 13, 2025
Maintains: Outperform
Price Target: $37 → $41
Current: $31.37
Upside: +30.70%
Dec 5, 2024
Maintains: Outperform
Price Target: $4 → $6
Current: $1.71
Upside: +251.91%
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $8.60
Upside: +190.70%
Aug 5, 2022
Maintains: Outperform
Price Target: $255 → $210
Current: $8.85
Upside: +2,272.88%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $3.66
Upside: +828.96%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $3.96
Upside: +5,708.08%